What can Big Pharma learn from an NYT bestseller?

What do blockbuster drugs have in common with Harry Potter and Lisbeth Salander? They're all mega-sellers in industries in which only two of every 7 big, risky bets pans out. So, Big Pharma could learn a trick or two from publishers, the Financial Times posits. Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.